These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25201862)

  • 21. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to: 'belimumab and the measurement of fatigue' by Mazzoni.
    Strand V; Levy RA; Cervera R; Petri M
    Ann Rheum Dis; 2015 Sep; 74(9):e54. PubMed ID: 25990291
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus.
    Kumthekar A; Danve A; Deodhar A
    J Rheumatol; 2017 Sep; 44(9):1416-1417. PubMed ID: 28864669
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.
    Zhang H; Chambers W; Sciascia S; Cuadrado MJ
    Expert Rev Clin Pharmacol; 2016; 9(5):681-94. PubMed ID: 26907827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous belimumab in the treatment of systemic lupus erythematosus.
    Elalouf O; Keeling SO; Touma Z
    Immunotherapy; 2018 Sep; 10(13):1163-1173. PubMed ID: 30105936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Belimumab--the biological drug for systemic lupus erythematosus: as discussed during the American College of Rheumatology (ACR) conference - 2012].
    Vadasz Z; Toubi E
    Harefuah; 2013 May; 152(5):304-6. PubMed ID: 23885457
    [No Abstract]   [Full Text] [Related]  

  • 27. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus.
    De Marchi G; Quartuccio L; Bond M; De Vita S
    Clin Exp Rheumatol; 2017; 35(6):1056. PubMed ID: 28770706
    [No Abstract]   [Full Text] [Related]  

  • 29. Systemic lupus erythematosus.
    Pearce L
    Nurs Stand; 2016 Jun; 30(43):17. PubMed ID: 27332581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus.
    Garcia A; De Sanctis JB
    Curr Pharm Des; 2016; 22(41):6306-6312. PubMed ID: 27587201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab.
    Hara M; Ogawa-Momohara M; Muro Y; Takeichi T; Akiyama M
    Eur J Dermatol; 2020 Oct; 30(5):615-617. PubMed ID: 32972910
    [No Abstract]   [Full Text] [Related]  

  • 32. Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open-label study.
    Sandhu VK; Wallace DJ; Weisman MH
    J Rheumatol; 2015 Apr; 42(4):728-30. PubMed ID: 25834243
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.
    Jüptner M; Zeuner R; Schreiber S; Laudes M; Schröder JO
    Lupus; 2014 Apr; 23(4):428-30. PubMed ID: 24482144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.
    Bishton M; Spencer A; Dickinson M; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):575-8. PubMed ID: 23773449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
    Simonetta F; Allali D; Roux-Lombard P; Chizzolini C
    Joint Bone Spine; 2017 Mar; 84(2):235-236. PubMed ID: 27238199
    [No Abstract]   [Full Text] [Related]  

  • 36. Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital.
    Riancho-Zarrabeitia L; Villa Blanco I; Santos-Gómez M; Aurrecoechea E
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):188-189. PubMed ID: 29555189
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
    Kadavath S; Bobic S; Efthimiou P
    Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
    Sjöwall C; Hjorth M; Eriksson P
    Lupus; 2017 Oct; 26(12):1333-1338. PubMed ID: 28162031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus.
    Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
    Ann Rheum Dis; 2020 Feb; 79(2):304-307. PubMed ID: 31712248
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of Belimumab for refractory systemic lupus erythematosus (SLE) involving the central nervous system.
    Cheng H; Zhao CS; Yan CL; Gao C; Wen HY
    Eur J Intern Med; 2021 Oct; 92():117-120. PubMed ID: 34226115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.